TY - JOUR
T1 - Distribution of adult T-cell leukaemia/lymphoma subtypes and survival outcomes across geographical regions
T2 - An international retrospective cohort study
AU - Valcarcel, Bryan
AU - Utsunomiya, Atae
AU - Otsuka, Maki
AU - Miyahara, Masaharu
AU - Ishitsuka, Kenji
AU - Takamatsu, Yasushi
AU - Suzumiya, Junji
AU - Tamura, Kazuo
AU - Vasquez, Jule F.
AU - Enriquez-Vera, Daniel
AU - Beltran, Brady E.
AU - Castro, Denisse
AU - Runciman, Thanya
AU - Idrobo, Henry
AU - Arrieta, Elizabeth
AU - Arias, Oriana
AU - Gotuzzo, Eduardo
AU - Garrido-Pinzás, Gabriela
AU - Rivera, Victor
AU - Rosa, Daniel La
AU - Peña, Camila
AU - Fiad, Lorena
AU - Ramos, Juan C.
AU - Sandoval-Sus, Jose
AU - Sica, Alejandro
AU - Bell, Britney N.
AU - Cook, Lucy B.
AU - Leataud, Veronica
AU - Miranda, Eliana C.M.
AU - Chiattone, Carlos
AU - Katsuya, Hiroo
AU - Malpica, Luis
N1 - Publisher Copyright:
© 2026 The Author(s). British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
PY - 2026/7
Y1 - 2026/7
N2 - Although adult T-cell leukaemia/lymphoma (ATL) has a higher burden in certain world regions, outcomes have not been directly compared across regions. We conducted a multicentre cohort study comparing the distribution of ATL subtypes and overall survival (OS) across 1090 adults (≥18 years) diagnosed with ATL during 2000–2023 in Japan (n = 366), South America (n = 364), the United States (n = 275) and the United Kingdom (n = 85). Survival was estimated using Kaplan–Meier methods. Acute ATL was more frequent in Japan (59%) than in the United States (45%), South America (36%) and the United Kingdom (24%) (pheterogeneity < 0.0001). Conversely, lymphomatous ATL predominated in the United Kingdom (53%), South America (51%) and the United States (45%) relative to Japan (20%) (pheterogeneity < 0.0001). With a median follow-up of 38 months interquartile range (IQR 14–68), 3-year OS across regions ranged from 10% to 25% for acute, 16%–34% for lymphomatous, 49%–86% for chronic and 60%–83% for smouldering ATL. Evidence of regional differences in OS was observed for acute, lymphomatous and chronic ATL but not for smouldering ATL. In conclusion, the distribution of ATL subtypes varies globally, and OS for aggressive subtypes (i.e. acute and aggressive) remains poor across regions. Our findings could guide the design of clinical studies aimed at developing accessible therapies through international collaboration.
AB - Although adult T-cell leukaemia/lymphoma (ATL) has a higher burden in certain world regions, outcomes have not been directly compared across regions. We conducted a multicentre cohort study comparing the distribution of ATL subtypes and overall survival (OS) across 1090 adults (≥18 years) diagnosed with ATL during 2000–2023 in Japan (n = 366), South America (n = 364), the United States (n = 275) and the United Kingdom (n = 85). Survival was estimated using Kaplan–Meier methods. Acute ATL was more frequent in Japan (59%) than in the United States (45%), South America (36%) and the United Kingdom (24%) (pheterogeneity < 0.0001). Conversely, lymphomatous ATL predominated in the United Kingdom (53%), South America (51%) and the United States (45%) relative to Japan (20%) (pheterogeneity < 0.0001). With a median follow-up of 38 months interquartile range (IQR 14–68), 3-year OS across regions ranged from 10% to 25% for acute, 16%–34% for lymphomatous, 49%–86% for chronic and 60%–83% for smouldering ATL. Evidence of regional differences in OS was observed for acute, lymphomatous and chronic ATL but not for smouldering ATL. In conclusion, the distribution of ATL subtypes varies globally, and OS for aggressive subtypes (i.e. acute and aggressive) remains poor across regions. Our findings could guide the design of clinical studies aimed at developing accessible therapies through international collaboration.
KW - HTLV-1
KW - adult T-cell leukaemia/lymphoma
KW - epidemiology
KW - prevalence
KW - survival
UR - https://www.scopus.com/pages/publications/105035905291
U2 - 10.1111/bjh.70494
DO - 10.1111/bjh.70494
M3 - Artículo
C2 - 41986288
AN - SCOPUS:105035905291
SN - 0007-1048
VL - 209
SP - 107
EP - 115
JO - British Journal of Haematology
JF - British Journal of Haematology
IS - 1
ER -